Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 20,726 shares at $1.53 ($32K) on 2015-09-04, disclosed to the SEC on 2015-09-04.
Scheduled sale ($32k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.52 | 12,526 | $19K | 60.2% |
| 2 | $1.53 | 5,500 | $8K | 26.6% |
| 3 | $1.54 | 1,000 | $2K | 4.9% |
| 4 | $1.54 | 1,700 | $3K | 8.3% |
| Total | $1.53 avg | 20,726 | $32K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |